FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Percutaneous transhepatic biliary drainage versus endoscopic ultrasound-guided biliary drainage with primary metal stenting for unresectable malignant distal biliary obstruction. PMID 42128368 · Endoscopy · 2026-Aug Study is a nonrandomized, non-inferiority trial comparing two procedural interventions (EUS-BD vs. PTBD) with primary metal stenting. It is not a randomized trial of a drug-containing intervention. The primary endpoint was technical success (categorical), but overall survival (a time-to-event endpoint) was also reported. However, the trial is not randomized and does not involve a drug intervention, thus failing key eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723. PMID 42119640 · Radiother Oncol · 2026-Aug The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result, but the primary and key secondary endpoints are efficacy outcomes (proportion of patients with nausea/vomiting events), not time-to-event endpoints. Therefore, it is excluded from the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial. PMID 42115521 · Diabetes Obes Metab · 2026-Aug This is a secondary analysis of the SPRINT trial focusing on stroke risk in hypertensive patients with prediabetes and cardiac biomarkers. It is not an oncology study, does not involve a drug-containing intervention (SPRINT's intervention was blood pressure target, not a specific drug), and is not a primary trial result but a subgroup analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial. PMID 42098550 · Ann Surg Oncol · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intranasal Ketamine for Existential Distress in Advanced Cancer. PMID 42055096 · J Pain Symptom Manage · 2026-Aug The record is an original report of a randomized controlled trial (RCT) in human oncology patients with a drug intervention (ketamine). However, it fails the time-to-event criterion as all reported outcomes are continuous patient-reported or clinician-rated scales (e.g., MADRS, GAD-7, MQOL) without any Kaplan-Meier, hazard ratio, or time-to-event endpoint (OS, PFS, etc.). Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the publication reports secondary outcomes. Therefore, it is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Visualization of Multi-indication Randomized Control Trial Evidence to Support Decision Making in Oncology: A Case Study on Bevacizumab. PMID 41913717 · Med Decis Making · 2026-Aug The record is a meta-analysis/methodological article synthesizing data from multiple trials of bevacizumab; it does not present new primary data from a single Phase III/IIIb or Phase II/III randomized controlled trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial. PMID 41880645 · J Urol · 2026-Aug Excluded because the study is single-arm, failing the randomization criterion. All other required criteria (oncology, human, phase 3, time-to-event, drug intervention, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integrated psychosocial, sleep, and immunonutritional intervention improves psychological adaptation, sleep disturbance, and inflammatory activation in rectal cancer: a randomized controlled trial. PMID 41714581 · Clin Transl Oncol · 2026-Aug The record describes a randomized, oncology, human trial with a primary time-to-event endpoint (DFS), but the intervention is a non-drug psychosocial, sleep, and nutritional program, not a drug-containing intervention. This violates the 'drug-containing intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials. PMID 42388346 · Liver Cancer · 2026-Apr-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Magnetic resonance imaging-based radiomics analysis: predicting vascular invasion in breast invasive ductal carcinoma using different machine learning models. PMID 42180954 · Transl Cancer Res · 2026-Apr-30 The record is a retrospective diagnostic/prognostic study evaluating MRI-based radiomics for predicting lymphovascular invasion in breast cancer. It is not a randomized clinical trial, does not assess a drug intervention, and does not report time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial. PMID 42170291 · Transl Lung Cancer Res · 2026-Apr-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Gastrointestinal and Variceal Bleeding Under Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Evidence from Trials to Real-World Practice. PMID 42122227 · Cancers (Basel) · 2026-Apr-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide. PMID 42066960 · Transplant Cell Ther · 2026-Apr-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. PMID 41662628 · Blood · 2026-Apr-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer. PMID 42187576 · Curr Oncol · 2026-Apr-29 This is a cross-sectional survey of global radiotherapy practices for early-stage glottic cancer, not a report of a randomized controlled trial. It does not involve a drug intervention, does not present time-to-event efficacy results (OS, PFS, DFS, etc.), and is not a primary, interim, or final result report of an oncology clinical trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of cyclosporine plus luspatercept versus cyclosporine in newly diagnosed non-transfusion-dependent non-severe aplastic anemia: A prospective randomized trial. PMID 42057135 · BMC Med · 2026-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial. PMID 42056728 · Int J Cancer · 2026-Apr-29 This is a randomized trial in early breast cancer patients, but the primary focus and reported endpoints are on chemotherapy-induced nausea and vomiting (CINV), which is a safety/toxicity outcome, not a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS). The study does not report a Kaplan-Meier curve or hazard ratio for tumor-related efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bone Mineral Density Does Not Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. PMID 42054252 · Dig Dis · 2026-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts. PMID 42049313 · BMJ Open · 2026-Apr-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. PMID 42047833 · Cancer Immunol Immunother · 2026-Apr-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fecal microbiota transplantation in reducing recurrence of colorectal adenomas after endoscopic resection: study protocol for a multicenter, open-label, randomized, no-treatment-controlled trial. PMID 42045958 · Trials · 2026-Apr-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer. PMID 42044963 · BMJ Open · 2026-Apr-27 This is a protocol for a randomized trial comparing radiotherapy techniques (brachytherapy vs. external beam radiotherapy) with a spacer gel. It is not a drug-containing intervention, is not reported as Phase III, and does not present results with a time-to-event efficacy endpoint. It is a protocol article without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of intraoperative use of 20% albumin in combination with Ringer's lactate versus Ringer's lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial). PMID 42044958 · BMJ Open · 2026-Apr-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Conducting a randomized controlled clinical trial on palliative care in patients with glioblastoma - what are the challenges? PMID 42043583 · Support Care Cancer · 2026-Apr-27 The record describes a sub-analysis of the EPCOG trial focusing on trial challenges (screening, attrition, protocol deviations). It is a randomized, human, oncology (glioblastoma) study. However, it is excluded because: 1) The intervention is specialized palliative care (non-drug), not a drug-containing intervention. 2) No time-to-event efficacy endpoint (e.g., OS, PFS) or its analysis (Kaplan-Meier, HR) is reported or signaled in the abstract. 3) The report type is a secondary analysis of trial conduct challenges, not the primary efficacy results of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study. PMID 42050422 · BMC Med Res Methodol · 2026-Apr-25 The article is a methodological guide and protocol description for a new trial design (ROCI), using a case study (REFINE-Lung) to illustrate the design. It does not report results of a completed Phase III or II/III randomized trial with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is excluded as a protocol-without-results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Preliminary analysis of mFOLFOXIRI plus bevacizumab combined with cytoreductive surgery for resectable peritoneal metastases from colorectal cancer: a prospective,randomized phase II clinical trial]. PMID 42045712 · Zhonghua Wei Chang Wai Ke Za Zhi · 2026-Apr-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Geriatric Oncology multidomain intervention study to prevent Cognitive impairment among older Indian patients with cancer receiving chemotherapy: a multicentric randomised controlled trial (GOCog). PMID 42034980 · BMC Geriatr · 2026-Apr-25 The record is a protocol for a randomized trial, not a results report. The primary endpoint is cognition (FACT-Cog), not a time-to-event efficacy endpoint. The trial phase is not specified. The intervention is non-drug (exercise + cognitive training), though chemotherapy is part of the standard care context. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Continuous Theta-Burst Stimulation on Postoperative Delirium in Older Patients Who Undergo Cardiac Surgery. PMID 42033441 · Neuromodulation · 2026-Apr-24 The study is a randomized trial in humans with a primary result, but it is not oncology, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). PMID 42033030 · J Natl Cancer Inst · 2026-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial. PMID 42031476 · BMJ Open · 2026-Apr-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial. PMID 42029635 · Clin Cancer Res · 2026-Apr-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer. PMID 41619866 · J Ethnopharmacol · 2026-Apr-24 The record describes a randomized, placebo-controlled clinical trial in advanced colorectal cancer with time-to-event endpoints (PFS, OS). However, the provided metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, the eligibility criterion cannot be fully established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Weifuchun inhibits gastric cancer metastasis by inhibiting angiogenesis mediated by the miR-139-5p/CXCR4 axis. PMID 41577154 · J Ethnopharmacol · 2026-Apr-24 The study is a randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (DFS) for gastric cancer. However, the phase of the trial (e.g., Phase III/IIIb or II/III) is not explicitly established in the provided title, abstract, metadata, or deterministic review signals. The deterministic review flagged 'phase3_evidence_unclear'. Therefore, the 'phase3_or_definitive' criterion cannot be confirmed, making the study ineligible under the strict criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial]. PMID 42086522 · Zhonghua Zhong Liu Za Zhi · 2026-Apr-23 The study is an oncology randomized trial with a drug intervention and reports overall survival, but the explicit trial phase is not provided in the metadata or abstract. The primary efficacy endpoint is a continuous measure (hemoglobin change), not a time-to-event endpoint. The time-to-event component (overall survival) is reported as a secondary endpoint with no statistically significant difference, but the absence of a primary/key secondary time-to-event endpoint (like OS or PFS) as the main focus for digitization makes it ineligible for this specific cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of a Modular App-Based Pelvic Floor Muscle Training Program for Postoperative Continence Recovery After Radical Prostatectomy: A Multi-Center Randomized Controlled Trial (PELVINTENSE Study). PMID 42122130 · Cancers (Basel) · 2026-Apr-22 The study is an oncology randomized controlled trial reporting primary results, but it evaluates a non-drug intervention (app-based pelvic floor muscle training) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is continence at 90 days (a binary outcome), not a time-to-event measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026. PMID 42025515 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42025514 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hybrid robot-assisted surgery versus conventional fully robotic surgery for colon cancer: study protocol for a multicenter, parallel-group, single-blind randomized controlled superiority trial. PMID 42021265 · BMC Surg · 2026-Apr-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. PMID 42019971 · J Immunother Cancer · 2026-Apr-22 The study is a randomized Phase III trial in oncology with a drug intervention and reports original results, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) in the provided abstract. The focus is on biomarker and single-cell analysis of treatment response, not clinical survival outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers. PMID 41384379 · Eur Heart J · 2026-Apr-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Topical Glucocorticosteroids for Proactive Therapy of Acute Radiation-Induced Skin Injury in Head and Neck Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. PMID 42072482 · Biomedicines · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial. PMID 42020258 · Eur Urol · 2026-Apr-21 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42020257 · Eur Urol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol. PMID 42015297 · Trials · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| NEO-HYPORT: does neoadjuvant radiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT). PMID 42015277 · Trials · 2026-Apr-21 The record describes a protocol for a randomized trial comparing neoadjuvant vs adjuvant radiotherapy (a non-drug intervention). It is not a report of original trial results with a drug intervention and a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial. PMID 42014146 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Study protocol, increasing awareness and early detection in students at risk of gynaecological cancer: feasibility of an online educational and behaviour change intervention. PMID 42010640 · Pilot Feasibility Stud · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Gonadotropin-releasing hormone agonist plus aromatase inhibitor versus oral progestins for fertility-sparing treatment in early endometrial carcinoma and atypical hyperplasia: interim analysis of a prospective controlled trial. PMID 42330749 · Int J Gynecol Cancer · 2026-Apr-20 This is an interim report of a prospective randomized controlled trial in oncology (early endometrial carcinoma/atypical hyperplasia) with a drug-containing intervention (GnRH agonist + aromatase inhibitor vs. progestins). However, it is not a Phase III/IIIb or Phase II/III definitive trial (phase is not specified as such, and the interim nature suggests it may be a smaller or earlier-phase study). More critically, the primary endpoint is complete response rate (a binary outcome), not a pre-specified time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or an endpoint reported via Kaplan-Meier/HR). Recurrence rates are mentioned but not as a primary/key secondary time-to-event endpoint with KM/HR. Therefore, it does not meet the core eligibility criteria for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013. PMID 42010655 · J Hematol Oncol · 2026-Apr-20 Eligibility criteria are met except for the explicit confirmation of a Phase III/IIIb or Phase II/III trial. The study is a randomized trial in human pediatric oncology with drug interventions and time-to-event endpoints (OS, EFS), presenting final comparative results. However, the phase is not explicitly declared in the provided information, and inference is not allowed per adjudication rules. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial. PMID 42002818 · Trials · 2026-Apr-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |